Teva launches Pataday generic
JERUSALEM — Teva on Friday announced the U.S. launch of its generic Pataday (olopatadine hydrochloride ophthalmic solution, 0.2%). The solution is a mast cell stabilizer indicated to treat ocular itching associated with allergic conjunctivitis.
“Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio,” Teva president and CEO global generic medicines Dipankar Bhattacharjee said. “This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market.”
Pataday had U.S. sales of approximately $303 million, according to data from QuintilesIMS for the 12 months ended March 2017.